Ravi F Iyer, Marieke C Verweij, Sujit S Nair, David Morrow, Mandana Mansouri, Dimple Chakravarty, Teresa Beechwood, Christine Meyer, Luke Uebelhoer, Elvin J Lauron, Andrea Selseth, Nessy John, Tin Htwe Thin, Siarhei Dzedzik, Colin Havenar-Daughton, Michael K Axthelm, Janet Douglas, Alan Korman, Nina Bhardwaj, Ashutosh K Tewari, Scott Hansen, Daniel Malouli, Louis J Picker, Klaus Früh
The nonpolymorphic major histocompatibility complex E (MHC-E) molecule is up-regulated on many cancer cells, thus contributing to immune evasion by engaging inhibitory NKG2A/CD94 receptors on NK cells and tumor-infiltrating T cells. To investigate whether MHC-E expression by cancer cells can be targeted for MHC-E-restricted T cell control, we immunized rhesus macaques (RM) with rhesus cytomegalovirus (RhCMV) vectors genetically programmed to elicit MHC-E-restricted CD8+ T cells and to express established tumor-associated antigens (TAAs) including prostatic acidic phosphatase (PAP), Wilms tumor-1 protein, or Mesothelin...
May 10, 2024: Science Advances